Northstar Neuroscience is a privately held corporation headquartered in Seattle, Washington. Our principal investors include:

The Company’s Board of Directors consists of:

• Susan Barnes
• Wende Hutton, Venture Partner, Canaan Partners
• Alan Levy, President & CEO, Northstar Neuroscience, Inc.
• Seth Rudnick, MD, General Partner, Canaan Partners
• Dale Spencer, Private Investor
• Jesse Treu, General Partner, Domain Associates
• Carol Winslow, Principal, Channel Medical Partners

For investor questions, please contact:
Ray Calvert
Vice President of Finance, CFO
Northstar Neuroscience, Inc.
rcalvert@northstarneuro.com
206.902.1930

Susan Barnes

Wende Hutton
Ms. Hutton is currently a Venture Partner at Canaan Partners. Ms. Hutton began her venture career at Mayfield in 1993, where she was a General Partner in the life sciences group. Recently, she was a General Partner at Spring Ridge Ventures, a health care-focused venture fund. Earlier in her career, Ms. Hutton held senior management positions at GenPharm International and Nellcor. Ms. Hutton has served on the board of directors for over 14 companies, and, in addition to her duties at Northstar, is currently a director of SenoRx and Alsius. Ms. Hutton holds an B.A. in human biology from Stanford University, and an MBA from Harvard Business School, where she was a Baker Scholar.

Alan Levy, Ph.D.
Dr. Levy is the President and CEO of Northstar Neuroscience. He has more than 30 years of experience in the medical products industry. Dr. Levy was formerly President and CEO of Heartstream, Inc., and President of Heart Technology, Inc., where he guided these companies through product development, several rounds of venture financing, FDA clearance and product launch, manufacturing scale-up, IPO's, and worldwide sales and distribution. He also served as Vice President of Research and New Product Development of Ethicon Inc., a division of Johnson & Johnson. Dr. Levy served on the board of Gynecare, Inc., a medical device company acquired by Johnson & Johnson, and currently serves on the boards of Intuitive Surgical Corporation and Proteus Biomedical. Dr. Levy received his B.S. in chemistry from City University of New York and his Ph.D. in organic chemistry from Purdue University.

Seth Rudnick, MD
Dr. Rudnick’s experience in the health care industry includes comprehensive experience in research, development, clinical trials analysis and biotechnology, as well as founding and growing start-up companies. Dr. Rudnick currently serves on the Board of Directors of Genaissance (GNSC), CombinatoRx, Immunicon (IMMC), Phylogix, Pintex, Sopherion, Spine Wave, Northstar, and several other private companies. Prior to joining Canaan, Mr. Rudnick served as CEO and Chairman at CytoTherapeutics (CTII). Before that, he helped found and served as head of R&D for Ortho Biotech, a division of Johnson & Johnson. In that role, he led development efforts for a portfolio of projects whose worldwide revenues now exceed $1 billion in annual sales. Dr. Rudnick’s academic career began when he served on the medical and public health faculty at University of North Carolina-Chapel Hill. Dr. Rudnick is a Clinical Professor of Medicine at University of North Carolina-Chapel Hill where he teaches and advises the faculty on biotechnology issues.

Dale Spencer
Mr. Spencer is a co-founder of ProtoStar, Inc., Velocimed, Inc., and founder of ev3, Inc. Previously, Mr. Spencer served as President, Chairman, and CEO of SciMed Life Systems, Inc., from 1980 until Boston Scientific acquired the company in 1995. Mr. Spencer joined SciMed in 1980 when the company’s sales were less than $1 million per year. At the time of the Boston Scientific merger, SciMed had annual sales of approximately $450 million and was a global leader in interventional cardiology products. Mr. Spencer served on the Board of Directors of Boston Scientific Corporation from 1995 to 1999, and also served as an Executive Vice President of Boston Scientific from 1995 to 1997. Mr. Spencer has served on the boards of 12 early-stage medical technology companies, and currently serves on the boards of 4 such companies and one public company. Mr. Spencer received a B.S. in engineering and an M.B.A. from the University of Illinois.

Jesse Treu, Ph.D.
Mr. Treu has been a General Partner of Domain Associates since its beginning in 1985. He has been a Director of over 20 early-stage healthcare companies, 13 of which subsequently went public. These include Biosite Diagnostics, GelTex Pharmaceuticals (acquired by Genzyme), Inspire Pharmaceuticals, NPS Pharmaceuticals, Sepracor, OraPharma (acquired by J&J), and Trimeris. Prior to the formation of Domain, Mr. Treu was V.P. of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology. Mr. Treu began his career at GE and was later an executive at Technicon Corporation (now part of Bayer Diagnostics). Mr. Treu has a B.S. from Rensselaer Polytechnic Institute and an M.A. and Ph.D. from Princeton University.

Carol Winslow
Ms. Winslow spent over 20 years in the medical technology industry, including 12 years of private and public medical technology investment experience, prior to founding CHANNEL Medical PartnersSM. She was the Senior Medical Device Analyst at Jefferies & Company, Inc., Vector Securities International, Inc., and Dain Bosworth Incorporated with responsibility for those firms' equity research activities within the medical technology industry. Earlier in her career, Ms. Winslow held a variety of management positions with Medtronic, Inc. She serves on the Board of Directors of the American Refugee Committee. Ms. Winslow received an A.B. degree from Mount Holyoke College and an M.B.A. from the University of Minnesota.